Type 2 Diabetes: Causes, Symptoms, and Progression

Type 2 diabetes is the most prevalent form of diabetes mellitus, accounting for approximately 90–95% of all diagnosed diabetes cases in the United States according to the Centers for Disease Control and Prevention (CDC). This page covers the biological mechanisms driving the condition, the risk factors and clinical scenarios most commonly associated with diagnosis, and the boundaries that distinguish type 2 diabetes from related metabolic conditions. Understanding the cause-and-effect chain — from insulin resistance through beta-cell exhaustion to chronic hyperglycemia — is foundational to understanding how endocrinologists approach evaluation and care. Readers seeking broader context on how this condition fits within the field can visit the endocrinology authority home.

Definition and scope

Type 2 diabetes mellitus is a chronic metabolic disorder characterized by progressive insulin resistance in peripheral tissues, impaired insulin secretion from pancreatic beta cells, and sustained elevation of blood glucose. The American Diabetes Association (ADA) defines the diagnostic threshold as a fasting plasma glucose of ≥126 mg/dL, a 2-hour plasma glucose of ≥200 mg/dL during an oral glucose tolerance test, or a hemoglobin A1c of ≥6.5% — each confirmed by repeat testing under normal clinical circumstances.

The CDC estimated that as of 2020, 37.3 million Americans — roughly 11.3% of the population — had diabetes, with the large majority holding a type 2 diagnosis (CDC National Diabetes Statistics Report). An additional 96 million adults had prediabetes, a precursor state defined by glucose metrics above normal but below the diagnostic threshold for diabetes.

Type 2 diabetes differs mechanistically from type 1 diabetes, which involves autoimmune destruction of beta cells and absolute insulin deficiency from disease onset. Type 2 involves relative — not absolute — insulin deficiency, arising from a combination of resistance and secretory dysfunction over time. This distinction governs clinical classification under the International Classification of Diseases codes (ICD-10-CM E11.x) maintained by the Centers for Medicare & Medicaid Services (CMS).

How it works

The pathophysiology of type 2 diabetes unfolds in stages, each reflecting a shift in the relationship between insulin supply and tissue demand.

Stage 1 — Insulin resistance: Skeletal muscle, liver, and adipose tissue become less responsive to insulin signaling. The pancreas compensates by secreting more insulin, maintaining near-normal glucose levels. This compensatory hyperinsulinemia can persist for years without clinical symptoms.

Stage 2 — Beta-cell stress and declining secretory capacity: Sustained demand on beta cells, combined with lipotoxicity and glucotoxicity from mild chronic hyperglycemia, accelerates beta-cell dysfunction. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) identifies this stage as the transition point at which fasting and postprandial glucose levels begin rising into the prediabetes range.

Stage 3 — Overt hyperglycemia: As beta-cell mass and function decline beyond the compensation threshold, fasting plasma glucose and A1c cross diagnostic thresholds. Hepatic glucose output rises unchecked because insulin can no longer suppress it effectively.

Stage 4 — Chronic complications: Sustained hyperglycemia drives glycosylation of proteins, oxidative stress, and microvascular and macrovascular damage. The primary complication targets — retina, kidney, peripheral nerves, and coronary vasculature — correspond to the recognized complication categories in ADA Standards of Medical Care in Diabetes.

A numbered breakdown of the core contributing risk factors, as identified by the CDC and NIDDK, includes:

  1. Obesity, particularly central adiposity — body mass index ≥30 kg/m²
  2. Physical inactivity — fewer than 150 minutes of moderate aerobic activity per week
  3. Family history of type 2 diabetes in a first-degree relative
  4. Age ≥45 years (though incidence in adults aged 18–44 has increased)
  5. History of gestational diabetes or delivery of a baby weighing more than 9 pounds
  6. Prediabetes (A1c 5.7–6.4% or fasting glucose 100–125 mg/dL)
  7. Race and ethnicity — Black, Hispanic, American Indian, Alaska Native, and Asian American populations face disproportionately higher prevalence per CDC surveillance data

Common scenarios

Three clinical presentations account for the majority of new type 2 diabetes diagnoses in adult endocrinology practice.

Incidental laboratory finding: A fasting glucose or A1c drawn during routine metabolic screening returns above threshold in a patient with no classic symptoms. This is the most common presentation pathway and underscores the CDC's finding that approximately 8.5 million Americans with diabetes in 2019 were undiagnosed.

Symptomatic polyuria/polydipsia syndrome: Classic symptoms — excessive thirst, frequent urination, blurred vision, and fatigue — develop when glucose levels exceed the renal reabsorption threshold of approximately 180 mg/dL. Patients may also report slow wound healing or recurrent skin infections, driven by impaired neutrophil function in hyperglycemic states.

Identified through complication workup: A patient presenting with peripheral neuropathy, proteinuria, or unexplained retinal changes undergoes metabolic evaluation and receives a diabetes diagnosis retrospectively. The NIDDK estimates that up to 50% of patients with type 2 diabetes already have some degree of peripheral neuropathy at the time of diagnosis, reflecting the silent progression of the prediabetes period.

Endocrinologists evaluating these presentations apply blood tests for endocrine conditions, including fasting glucose, A1c, and C-peptide, to characterize residual insulin secretion capacity before selecting a management approach.

Decision boundaries

Distinguishing type 2 diabetes from other forms of diabetes requires attention to specific clinical markers that separate categories with meaningfully different management pathways.

Type 2 vs. Type 1: Type 2 diabetes typically presents in adults over 35 with obesity and gradual onset; type 1 can present at any age with rapid onset, weight loss, and ketosis. C-peptide levels above 0.6 ng/mL generally indicate preserved beta-cell function consistent with type 2. Positive islet cell antibodies (GAD65, IA-2, ZnT8) shift the classification toward autoimmune type 1 or latent autoimmune diabetes in adults (LADA). Per ADA Standards, antibody testing is indicated when clinical presentation is ambiguous.

Type 2 vs. MODY: Maturity-onset diabetes of the young (MODY) is a monogenic form caused by single-gene mutations (commonly GCK, HNF1A, or HNF4A) that mimics type 2 in non-obese patients with a strong multigenerational family history. Genetic testing confirms or excludes MODY. MODY subtypes may not require insulin or standard oral agents, making correct classification clinically significant.

Type 2 vs. secondary diabetes: Endocrine disorders — including Cushing's syndrome, acromegaly, and hyperparathyroidism — can produce sustained hyperglycemia through hormone-driven insulin resistance. Secondary diabetes resolves or substantially improves when the underlying hormonal excess is corrected. The regulatory and oversight framework governing diagnostic coding distinguishes secondary diabetes under separate ICD-10-CM categories (E08.x, E09.x, E13.x) from primary type 2 (E11.x).

Prediabetes threshold management: Patients with A1c values of 5.7–6.4% or fasting glucose of 100–125 mg/dL occupy a clinical boundary zone. The ADA and NIDDK both recommend intensive lifestyle intervention at this stage — targeting a minimum 7% body weight reduction in overweight individuals — based on outcomes from the Diabetes Prevention Program, a landmark randomized controlled trial supported by the National Institutes of Health (NIH).

Monitoring tools including hemoglobin A1c and continuous glucose monitoring allow clinicians to track glycemic trajectory across these boundaries over time, informing when reclassification or escalation of therapy is warranted.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)